These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23480323)

  • 1. Antipsychotic-induced dyslipidemia treated with omega 3 fatty acid supplement in an 11-year-old psychotic child: a 1-year follow-up.
    Pisano S; Gritti A; Catone G; Pascotto A
    J Child Adolesc Psychopharmacol; 2013 Mar; 23(2):139-41. PubMed ID: 23480323
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report.
    Lin SK; Chen CK
    J Clin Psychiatry; 2006 Aug; 67(8):1307. PubMed ID: 16965214
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of long-term use of risperidone on body weight of children with an autism spectrum disorder.
    Demb H; Valicenti-McDermott M; Navarro A; Ayoob KT
    J Clin Psychopharmacol; 2011 Oct; 31(5):669-70. PubMed ID: 21881456
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperprolactinemia in an adolescent with psychotic disorder on risperidone.
    Jummani R; Coffey BJ
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):791-4. PubMed ID: 20035598
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe depression with risperidone-induced EPS in an elderly schizoaffective patient.
    Benazzi F
    Can J Psychiatry; 1996 Apr; 41(3):196-7. PubMed ID: 8722655
    [No Abstract]   [Full Text] [Related]  

  • 6. A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents.
    Swadi HS; Craig BJ; Pirwani NZ; Black VC; Buchan JC; Bobier CM
    Int Clin Psychopharmacol; 2010 Jan; 25(1):1-6. PubMed ID: 19809337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic ketoacidosis associated with risperidone treatment?
    Croarkin PE; Jacobs KM; Bain BK
    Psychosomatics; 2000; 41(4):369-70. PubMed ID: 10906363
    [No Abstract]   [Full Text] [Related]  

  • 8. Amoxapine as an atypical antipsychotic: a comparative study vs risperidone.
    Apiquian R; Fresan A; Ulloa RE; de la Fuente-Sandoval C; Herrera-Estrella M; Vazquez A; Nicolini H; Kapur S
    Neuropsychopharmacology; 2005 Dec; 30(12):2236-44. PubMed ID: 15956984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
    Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
    Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone side effects.
    Edleman RJ
    J Am Acad Child Adolesc Psychiatry; 1996 Jan; 35(1):4-5. PubMed ID: 8567610
    [No Abstract]   [Full Text] [Related]  

  • 11. Symptomatic bradyarrhythmia secondary to risperidone.
    Goyal RS; Goyal SB
    Am J Psychiatry; 2003 Dec; 160(12):2243. PubMed ID: 14638604
    [No Abstract]   [Full Text] [Related]  

  • 12. [Risperidone in the early treatment of first-episode psychosis: a two-year follow-up study].
    Gutiérrez Fraile M; Segarra Echevarría R; González-Pinto Arrillaga A; Martínez Junquera G
    Actas Esp Psiquiatr; 2002; 30(3):142-52. PubMed ID: 12106515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone-associated steatohepatitis and excessive weight-gain.
    Holtmann M; Kopf D; Mayer M; Bechtinger E; Schmidt MH
    Pharmacopsychiatry; 2003 Sep; 36(5):206-7. PubMed ID: 14571356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up.
    Attux C; Quintana MI; Chaves AC
    Braz J Psychiatry; 2007 Dec; 29(4):346-9. PubMed ID: 17992359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities].
    Kostulski A; Wyszogrodzka-Kucharska A; Rabe-Jabłońska J
    Przegl Lek; 2005; 62(9):938-43. PubMed ID: 16541734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of risperidone-induced priapism.
    Relan P; Gupta N; Mattoo SK
    J Clin Psychiatry; 2003 Apr; 64(4):482-3. PubMed ID: 12716256
    [No Abstract]   [Full Text] [Related]  

  • 17. Medication-induced weight gain and dyslipidemia in patients with schizophrenia.
    Fenton WS; Chavez MR
    Am J Psychiatry; 2006 Oct; 163(10):1697-704; quiz 1858-9. PubMed ID: 17012676
    [No Abstract]   [Full Text] [Related]  

  • 18. Risperidone and tardive dyskinesia: a case report.
    Addington DE; Toews JA; Addington JM
    J Clin Psychiatry; 1995 Oct; 56(10):484-5. PubMed ID: 7559377
    [No Abstract]   [Full Text] [Related]  

  • 19. [Benefit of early prescription of Risperdal RLAI: a study of 25 psychotic patients hospitalised for the first time in their district service].
    Viala A; Cornic F; Beghelli F; Vacheron MN
    Therapie; 2010; 65(6):579-80. PubMed ID: 21176766
    [No Abstract]   [Full Text] [Related]  

  • 20. Risperidone questioned as dementia first-line treatment.
    Saxe T
    Geriatrics; 2004 Feb; 59(2):11; author reply 11-2. PubMed ID: 14989589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.